Thyme Care raises $95 million in Series C funding

Thyme carea Nashville, Tennessee-based value-based cancer care provider, has raised $95 million in Series C funding.

The round was led by Concord Health Partners, with participation from all existing investors, including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital. Banc of California will provide an additional $40 million in debt financing, bringing the total amount raised by Thyme Care to date to $178 million.

The company intends to use the funds to grow and scale its business by expanding into new markets, investing in existing partnerships in oncology, primary care and health insurance, and deepening its clinical value-based care model.

Led by CEO Robin Shah, Thyme Care is a care delivery company that partners with payers, employers and risk-bearing providers to take responsibility for improved quality of care, improved health outcomes and lower total cost of care. Its approach combines a technology-enabled care team and integration with more than 800 oncologists in Thyme Care Oncology Partners, creating a hybrid, collaborative care model that guides and supports the entire patient journey. Its suite of services, including 24/7 specialized cancer care navigation services, technology and data insights, and provider-led therapeutic interventions, enable a patient experience and promote sustainability across the ecosystem. Through its Medicare Advantage and commercial payer agreements and its collaboration in CMS’ Enhancing Oncology Model (EOM), Thyme Care takes financial responsibility for oncology populations at scale to reduce total cost of care and improve outcomes and experiences.

FinSMEs

16.07.2024